These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 15942022

  • 1. Down-regulation of DNA topoisomerase IIalpha leads to prolonged cell cycle transit in G2 and early M phases and increased survival to microtubule-interacting agents.
    Skladanowski A, Côme MG, Sabisz M, Escargueil AE, Larsen AK.
    Mol Pharmacol; 2005 Sep; 68(3):625-34. PubMed ID: 15942022
    [Abstract] [Full Text] [Related]

  • 2. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
    Morgan SE, Cadena RS, Raimondi SC, Beck WT.
    Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
    [Abstract] [Full Text] [Related]

  • 3. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
    Matsumoto Y, Takano H, Nagao S, Fojo T.
    Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
    [Abstract] [Full Text] [Related]

  • 4. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
    Khélifa T, René B, Le Mée S, Lambert B, Saucier JM, Markovits J, Jacquemin-Sablon H, Jacquemin-Sablon A.
    Cancer Res; 1999 Oct 01; 59(19):4927-36. PubMed ID: 10519406
    [Abstract] [Full Text] [Related]

  • 5. A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs.
    Jensen LH, Liang H, Shoemaker R, Grauslund M, Sehested M, Hasinoff BB.
    Mol Pharmacol; 2006 Nov 01; 70(5):1503-13. PubMed ID: 16880287
    [Abstract] [Full Text] [Related]

  • 6. Drastic reduction of topoisomerase II alpha associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth.
    Hashimoto S, Chatterjee S, Ranjit GB, Bao C, Ford J, Ganapathi R, Berger SJ, Berger NA.
    Oncol Res; 1995 Nov 01; 7(7-8):407-16. PubMed ID: 8747604
    [Abstract] [Full Text] [Related]

  • 7. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
    Chen S, Gomez SP, McCarley D, Mainwaring MG.
    Cancer Chemother Pharmacol; 2002 May 01; 49(5):347-55. PubMed ID: 11976828
    [Abstract] [Full Text] [Related]

  • 8. Glucose-regulated stresses cause degradation of DNA topoisomerase IIalpha by inducing nuclear proteasome during G1 cell cycle arrest in cancer cells.
    Kim HD, Tomida A, Ogiso Y, Tsuruo T.
    J Cell Physiol; 1999 Jul 01; 180(1):97-104. PubMed ID: 10362022
    [Abstract] [Full Text] [Related]

  • 9. Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors.
    Jensen LH, Thougaard AV, Grauslund M, Søkilde B, Carstensen EV, Dvinge HK, Scudiero DA, Jensen PB, Shoemaker RH, Sehested M.
    Cancer Res; 2005 Aug 15; 65(16):7470-7. PubMed ID: 16103101
    [Abstract] [Full Text] [Related]

  • 10. Mitosis-specific MPM-2 phosphorylation of DNA topoisomerase IIalpha is regulated directly by protein phosphatase 2A.
    Escargueil AE, Larsen AK.
    Biochem J; 2007 Apr 15; 403(2):235-42. PubMed ID: 17212588
    [Abstract] [Full Text] [Related]

  • 11. Changes in subcellular distribution of topoisomerase IIalpha correlate with etoposide resistance in multicell spheroids and xenograft tumors.
    Oloumi A, MacPhail SH, Johnston PJ, Banáth JP, Olive PL.
    Cancer Res; 2000 Oct 15; 60(20):5747-53. PubMed ID: 11059769
    [Abstract] [Full Text] [Related]

  • 12. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
    Marchion DC, Bicaku E, Turner JG, Daud AI, Sullivan DM, Munster PN.
    Clin Cancer Res; 2005 Dec 01; 11(23):8467-75. PubMed ID: 16322310
    [Abstract] [Full Text] [Related]

  • 13. Activation of the unfolded protein response is necessary and sufficient for reducing topoisomerase IIalpha protein levels and decreasing sensitivity to topoisomerase-targeted drugs.
    Gray MD, Mann M, Nitiss JL, Hendershot LM.
    Mol Pharmacol; 2005 Dec 01; 68(6):1699-707. PubMed ID: 16141312
    [Abstract] [Full Text] [Related]

  • 14. Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha.
    Herzog CE, Holmes KA, Tuschong LM, Ganapathi R, Zwelling LA.
    Cancer Res; 1998 Dec 01; 58(23):5298-300. PubMed ID: 9850052
    [Abstract] [Full Text] [Related]

  • 15. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human and mouse breast cancer cells.
    Asano T, Kleinerman ES, Zwelling LA, Zhou Z, Fukunaga Y.
    Acta Oncol; 2005 Dec 01; 44(3):240-7. PubMed ID: 16076696
    [Abstract] [Full Text] [Related]

  • 16. E1A specifically enhances sensitivity to topoisomerase IIalpha targeting anticancer drug by up-regulating the promoter activity.
    Zhou Z, Guan H, Kleinerman ES.
    Mol Cancer Res; 2005 May 01; 3(5):271-5. PubMed ID: 15886298
    [Abstract] [Full Text] [Related]

  • 17. A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors.
    Liang H, Wu X, Yalowich JC, Hasinoff BB.
    Mol Pharmacol; 2008 Mar 01; 73(3):686-96. PubMed ID: 18045852
    [Abstract] [Full Text] [Related]

  • 18. Functional compatibility between isoform alpha and beta of type II DNA topoisomerase.
    Sakaguchi A, Kikuchi A.
    J Cell Sci; 2004 Mar 01; 117(Pt 7):1047-54. PubMed ID: 14996935
    [Abstract] [Full Text] [Related]

  • 19. Topoisomerase IIalpha inhibition following DNA transfection greatly enhances random integration in a human pre-B lymphocyte cell line.
    Toyoda E, Kurosawa A, Kamekawa H, Adachi N.
    Biochem Biophys Res Commun; 2009 May 08; 382(3):492-6. PubMed ID: 19285952
    [Abstract] [Full Text] [Related]

  • 20. Salvicine functions as novel topoisomerase II poison by binding to ATP pocket.
    Hu CX, Zuo ZL, Xiong B, Ma JG, Geng MY, Lin LP, Jiang HL, Ding J.
    Mol Pharmacol; 2006 Nov 08; 70(5):1593-601. PubMed ID: 16914642
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.